Cite

HARVARD Citation

    Lythgoe, M. et al. (2021). How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyond. European journal of cancer. pp. 68-70. [Online]. 
  
Back to record